Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients

The gut microbiome has been linked to the pathogenesis of type 1 diabetes (T1D), identifying it as a promising therapeutic target. Nutritional interventions, which are an effective way to modulate the gut microbiome, thus show potential to be applied as complementary therapies for T1D. One particula...

Full description

Saved in:
Bibliographic Details
Main Authors: Franziska A. Graef, Bettina Berger, Lina S. Bahr, Rainer Stange, Andreas Michalsen, Friedemann Paul, Bruce A. Vallance, Kevan Jacobson
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1623800/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849237987774169088
author Franziska A. Graef
Bettina Berger
Lina S. Bahr
Rainer Stange
Rainer Stange
Andreas Michalsen
Andreas Michalsen
Friedemann Paul
Friedemann Paul
Bruce A. Vallance
Kevan Jacobson
author_facet Franziska A. Graef
Bettina Berger
Lina S. Bahr
Rainer Stange
Rainer Stange
Andreas Michalsen
Andreas Michalsen
Friedemann Paul
Friedemann Paul
Bruce A. Vallance
Kevan Jacobson
author_sort Franziska A. Graef
collection DOAJ
description The gut microbiome has been linked to the pathogenesis of type 1 diabetes (T1D), identifying it as a promising therapeutic target. Nutritional interventions, which are an effective way to modulate the gut microbiome, thus show potential to be applied as complementary therapies for T1D. One particular dietary intervention, prolonged therapeutic fasting, has been shown to ameliorate symptoms of several autoimmune diseases, while also modifying the gut microbiota composition of healthy populations. It is unclear, however, how the gut microbiota of patients suffering from diseases of autoimmunity will respond to fasting. In this pilot study, we investigate the effects of prolonged fasting on the gut microbiome of T1D patients: Fasting substantially changed the composition and structure of the T1D gut microbiome so that it converged with that of non-diabetic controls immediately post fasting. Moreover, a comparison with a population of patients suffering from Multiple Sclerosis revealed substantial overlap in post-fasted microbiome changes and a remarkable consistency with published data of non-autoimmune populations, indicating that fasting leads to signature microbiome changes that are independent of host health status and disease type. A correlation analysis between fasting-mediated microbiota modifications and changes in clinical parameters revealed several significant associations between the Oscillospiraceae and Lachnospiraceae families and cholesterol and blood pressure changes in the T1D cohort, corroborating previous studies reporting on these associations in non-diabetic subjects. In conclusion, the observed fasting-mediated microbiome signature suggests that nutrient availability is a major disease-independent factor in shaping gut microbiome composition, likely driven by the need for metabolic diversification of microbial nutrient acquisition. The corresponding clinical associations highlight the need to investigate if these fasting-driven changes in the reported taxa are causally linked to the recorded clinical benefits of therapeutic fasting and what importance fasting as an additional therapeutic intervention might have to improve long term conditions in people with T1D.
format Article
id doaj-art-6ff6c11a6edd4e5e978128a20bcb7ff9
institution Kabale University
issn 1664-2392
language English
publishDate 2025-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj-art-6ff6c11a6edd4e5e978128a20bcb7ff92025-08-20T04:01:47ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-08-011610.3389/fendo.2025.16238001623800Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patientsFranziska A. Graef0Bettina Berger1Lina S. Bahr2Rainer Stange3Rainer Stange4Andreas Michalsen5Andreas Michalsen6Friedemann Paul7Friedemann Paul8Bruce A. Vallance9Kevan Jacobson10Department of Pediatrics, BC Children’s Hospital, University of British Columbia, Vancouver, BC, CanadaChair of Medical Theory, Integrative and Anthroposophic Medicine, Faculty of Health, Witten/Herdecke University, Witten, GermanyNeuroCure Clinical Research Center and Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität Berlin, Berlin, GermanyInstitute of Social Medicine, Epidemiology & Health Economics, Charité - Universitätsmedizin Berlin, Berlin, GermanyDepartment of Internal and Integrative Medicine, Immanuel Hospital Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyInstitute of Social Medicine, Epidemiology & Health Economics, Charité - Universitätsmedizin Berlin, Berlin, GermanyDepartment of Internal and Integrative Medicine, Immanuel Hospital Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyNeuroCure Clinical Research Center and Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität Berlin, Berlin, GermanyExperimental and Clinical Research Center, a cooperation between Charité - Universitätsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Berlin, GermanyDepartment of Pediatrics, BC Children’s Hospital, University of British Columbia, Vancouver, BC, CanadaDepartment of Pediatrics, BC Children’s Hospital, University of British Columbia, Vancouver, BC, CanadaThe gut microbiome has been linked to the pathogenesis of type 1 diabetes (T1D), identifying it as a promising therapeutic target. Nutritional interventions, which are an effective way to modulate the gut microbiome, thus show potential to be applied as complementary therapies for T1D. One particular dietary intervention, prolonged therapeutic fasting, has been shown to ameliorate symptoms of several autoimmune diseases, while also modifying the gut microbiota composition of healthy populations. It is unclear, however, how the gut microbiota of patients suffering from diseases of autoimmunity will respond to fasting. In this pilot study, we investigate the effects of prolonged fasting on the gut microbiome of T1D patients: Fasting substantially changed the composition and structure of the T1D gut microbiome so that it converged with that of non-diabetic controls immediately post fasting. Moreover, a comparison with a population of patients suffering from Multiple Sclerosis revealed substantial overlap in post-fasted microbiome changes and a remarkable consistency with published data of non-autoimmune populations, indicating that fasting leads to signature microbiome changes that are independent of host health status and disease type. A correlation analysis between fasting-mediated microbiota modifications and changes in clinical parameters revealed several significant associations between the Oscillospiraceae and Lachnospiraceae families and cholesterol and blood pressure changes in the T1D cohort, corroborating previous studies reporting on these associations in non-diabetic subjects. In conclusion, the observed fasting-mediated microbiome signature suggests that nutrient availability is a major disease-independent factor in shaping gut microbiome composition, likely driven by the need for metabolic diversification of microbial nutrient acquisition. The corresponding clinical associations highlight the need to investigate if these fasting-driven changes in the reported taxa are causally linked to the recorded clinical benefits of therapeutic fasting and what importance fasting as an additional therapeutic intervention might have to improve long term conditions in people with T1D.https://www.frontiersin.org/articles/10.3389/fendo.2025.1623800/fulltype 1 diabetesfastingtherapeutic fastinggut microbiomegut bacterianutrient availability
spellingShingle Franziska A. Graef
Bettina Berger
Lina S. Bahr
Rainer Stange
Rainer Stange
Andreas Michalsen
Andreas Michalsen
Friedemann Paul
Friedemann Paul
Bruce A. Vallance
Kevan Jacobson
Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients
Frontiers in Endocrinology
type 1 diabetes
fasting
therapeutic fasting
gut microbiome
gut bacteria
nutrient availability
title Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients
title_full Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients
title_fullStr Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients
title_full_unstemmed Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients
title_short Fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients
title_sort fasting elicits gut microbiome signature changes that extend to type 1 diabetes patients
topic type 1 diabetes
fasting
therapeutic fasting
gut microbiome
gut bacteria
nutrient availability
url https://www.frontiersin.org/articles/10.3389/fendo.2025.1623800/full
work_keys_str_mv AT franziskaagraef fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT bettinaberger fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT linasbahr fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT rainerstange fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT rainerstange fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT andreasmichalsen fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT andreasmichalsen fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT friedemannpaul fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT friedemannpaul fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT bruceavallance fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients
AT kevanjacobson fastingelicitsgutmicrobiomesignaturechangesthatextendtotype1diabetespatients